The Phase 3 A-LONG study demonstrated the safety and efficacy of rFVIIIFc for the control and prevention of bleeding episodes in severe haemophilia A. Aim: To describe the treatment of bleeding episodes with rFVIIIFc in the A-LONG study. Methods: A-LONG subjects (<1 IU dL À1 endogenous FVIII) were treated with individualized prophylaxis (Arm 1), weekly prophylaxis (Arm 2) or episodic treatment (Arm 3). Information recorded for each bleeding episode included type, location and dose to treat the episode. Results: During A-LONG, 757 bleeding episodes occurred during the efficacy period; the majority [456 (60%)] occurred in Arm 3 (episodic treatment). Of 93 subjects in the prophylaxis arms who entered the study with target joints, 43 (60%) in Arm 1 and 11 (52%) in Arm 2 did not experience a target joint bleed. Overall, 98% of bleeding episodes (and 98% of bleeds involving a target joint) resolved with one or two infusions; the median dose per infusion to treat a bleed was 27 IU kg À1 (27 IU kg À1 for target joints). Using population pharmacokinetic simulations, FVIII activity levels were predicted to be below the upper limit of normal (150 IU dL
Introduction
Replacement factor VIII (FVIII) is used to prevent and treat bleeding episodes in people with haemophilia A [1] . Although replacement factor prophylaxis is the standard of care for individuals with severe haemophilia A, some individuals use replacement factor solely for treatment of bleeding episodes (episodic or ondemand therapy), often due to resource constraints [1] or inability to maintain a prophylactic regimen, which often requires frequent infusions (3-4 times week À1 ) [2] . Individuals on prophylaxis may also require treatment for breakthrough bleeding episodes.
A prophylactic regimen with a reduced infusion frequency could potentially improve adherence, which may ultimately improve clinical outcomes [3, 4] . The Phase 3 A-LONG study confirmed the prolonged halflife of recombinant factor VIII Fc fusion protein (rFVIIIFc) vs. conventional recombinant factor VIII (rFVIII) and demonstrated the efficacy and safety of rFVIIIFc for the prevention and treatment of bleeding episodes in previously treated subjects with severe haemophilia A [5] . Low bleeding rates were observed for A-LONG subjects treated prophylactically in the rFVIIIFc extension study, ASPIRE (NCT1454739) [6] .
Assessment of efficacy of rFVIIIFc for all bleeding episodes, both for episodic use and treatment of bleeding events during prophylaxis, is important. As joint bleeding is common in people with haemophilia A [7] , the occurrence of target joint bleeds and efficacy of rFVIIIFc for treatment of those events is important. Here, we describe the treatment of bleeding episodes with rFVIIIFc in the A-LONG trial, including the occurrence of target joint bleeds for subjects using rFVIIIFc prophylaxis, and the efficacy of rFVIIIFc for the treatment of bleeding episodes both in general and involving target joints. Finally, for individuals on prophylaxis, minimizing time spent >150 IU dL À1 factor activity level after bleeding episode treatment, in addition to an ongoing infusion regimen, is key because high factor activity levels over an extended period of time could theoretically contribute to adverse events such as unmasking of subclinical atherosclerotic disease with subsequent vascular thrombosis [8, 9] . To this end, we use population pharmacokinetic modelling to predict FVIII activity levels over time for the use of rFVIIIFc to treat a bleeding episode in close proximity (i.e. 24 h) to a scheduled prophylactic dose.
Materials and methods

Study design and population
A-LONG was a Phase 3 study evaluating the safety, efficacy and pharmacokinetics of rFVIIIFc [5] . The study included three treatment arms: Arm 1, individualized prophylaxis; Arm 2, weekly prophylaxis; and Arm 3, episodic treatment. Males with severe haemophilia A (<1 IU dL À1 endogenous FVIII level) were eligible for enrolment; study design and population have been published [5] and are summarized here (Data S1).
Management of bleeding episodes
Dosing of rFVIIIFc to treat a bleeding episode was based on the subject's clinical condition and known pharmacokinetic information, and type and severity of bleeding [1] . The study protocol suggested guidelines for bleeding episode management (Data S1).
Information on bleeding events was obtained from electronic patient diaries and medical records while the subject received treatment (Data S1). Bleeding episode severity was not collected.
Outcome measures
Outcomes included number of infusions required to resolve a bleed, rFVIIIFc dose administered per infusion and total rFVIIIFc dose per bleeding episode. Additionally, subjects' assessment of response to treatment of a bleed with rFVIIIFc, performed within 8-12 h from the time the rFVIIIFc infusion was given to treat the bleed, and physicians' global assessment of response to the rFVIIIFc regimen throughout the study, performed at study visits, were evaluated (Data S1).
Analyses
Descriptive analyses included median and interquartile range (IQR) values. Categorical data were summarized using frequency and percent. The number of subjects or total number of bleeding episodes was used as the denominator where applicable, with the following exception: for the summary of bleeding episode locations, the total number of bleeding episode locations was used as the denominator, as a single bleeding episode could involve ≥1 location (e.g. a traumatic bleeding episode might involve muscle and skin/mucosa). A target joint was defined in the protocol as a major joint (e.g. hip, elbow, wrist, shoulder, knee, ankle) into which repeated bleeding occurs (frequency of ≥3 bleeding episodes into the same joint in a consecutive 6-month period). Prestudy joint annualized bleeding rate (ABR) was based on each subject's self-reported number of joint bleeding episodes during the 12 months before the study (based on patient logs and/or clinic records). Post hoc analysis of prestudy vs. on-study joint ABR comparisons was performed using the signed rank test.
Population pharmacokinetic simulations
A previously validated, two-compartment rFVIIIFc population pharmacokinetic model [base model including below the limit of quantitation (BLQ)] [10] was used to predict factor activity levels in 1000 hypothetical patients. Factor activity was modelled under six scenarios with a 25 IU kg À1 dose of rFVIIIFc used for the treatment of bleeding episode 24 h before or 24 h after a scheduled prophylactic dose for patients at steady-state on a regimen of 50 IU kg À1 every 3, 4 or 5 days.
Results
Subjects
As reported previously [5] , 165 subjects were enrolled in A-LONG. Demographic and baseline characteristics for these subjects were consistent with those of a population with severe haemophilia A ( Table S1 ).
Summary of bleeding episodes
Of the 163 subjects evaluable for efficacy, 55% of subjects in Arm 1, 83% of subjects in Arm 2 and 100% of subjects in Arm 3 experienced ≥1 bleeding episode during the study period. Of the 757 bleeding episodes that occurred across the three treatment arms, the majority [456 (60%)] occurred in the episodic arm (Arm 3). The types and locations of bleeding episodes are summarized in Table 1 .
In the prophylactic treatment arms [individualized (Arm 1) and weekly (Arm 2) prophylaxis], 95 subjects had ≥1 target joint at study entry. Bleeding data during the efficacy period (for Arms 1 and 2, the efficacy period started with the first prophylactic rFVIIIFc dose following the completed pharmacokinetic sampling period and ended with the last rFVIIIFc dose administered) were available for 93 of these 95 subjects with target joints at study entry, including 72 subjects in Arm 1 [median (IQR) time on study, 32 (29, 38) weeks] and 21 subjects in Arm 2 [median (IQR) time on study, 28 (26, 29) weeks]. With rFVIIIFc prophylaxis, the median (IQR) target joint ABR was 0.0 (0.0, 3.0) and 0.0 (0.0, 1.9) in Arms 1 and 2, respectively, in subjects entering the study with target joints. In Arm 1, 43 (60%) of these subjects did not experience any target joint bleeds on study; among subjects in Arm 2, 11 (52%) did not experience any target joint bleeds on study. Compared with subject-reported prestudy joint ABR, there was a significant reduction (P < 0.001) in on-study joint ABR in subjects with target joints at baseline ( One subject in Arm 1 was excluded from efficacy analyses because he did not receive rFVIIIFc. ‡ One subject in Arm 2 was excluded from efficacy analyses because he withdrew from the study after the pharmacokinetic evaluations (no efficacy assessments could be made). § A single bleeding episode could involve ≥1 location (e.g. a traumatic bleeding episode might occur in muscle and skin/mucosa). ¶
The most common joint sublocations were: Arm 1, 29% ankle, 28% elbow, 24% knee; Arm 2, 46% elbow, 25% knee, 17% ankle; and Arm 3, 33% elbow, 29% ankle, 17% knee. Prestudy vs. on-study joint and target joint ABR in subjects with target joints at baseline (the subset of subjects with non-missing data for both prestudy and on-study joint ABR, according to prestudy treatment regimen and on-study prophylactic regimen). ABR, annualized bleeding rate; IQR, interquartile range; rFVIII, recombinant factor VIII; rFVIIIFc, recombinant factor VIII Fc fusion protein. *P < 0.001 for prestudy vs. onstudy joint ABR.
bleeding episodes assessed by location and type (data not shown). Furthermore, 98% of bleeds overall were resolved with one or two infusions, with similar results for each treatment arm (data not shown). Of bleeding episodes involving target joints, 87% resolved with one infusion; 98% resolved with one or two infusions.
Dose. In the overall population, the median rFVIIIFc dose per infusion to treat a bleeding episode was 27 IU kg À1 (Fig. 2) . The median total rFVIIIFc doses per bleeding episode were 33, 30 and 27 IU kg À1 for Arms 1, 2 and 3, respectively, and 28 IU kg À1 for the total population, consistent with the observation that the majority of bleeds required one infusion for resolution. For bleeding episodes involving target joints, the median total dose to treat a bleed for the overall population was 28 IU kg
À1
; for spontaneous and traumatic bleeding episodes, these values were 28 and 29 IU kg À1 respectively.
Assessment of response to treatment
Subjects assessed response to treatment within 8-12 h after the infusion, which was 12-16 h prior to making a decision regarding whether to treat with a second infusion. The majority (78%) of rFVIIIFc infusions were rated by subjects as producing an 'excellent' or 'good' response; similar assessments were made for bleeding episodes involving target joints and traumatic bleeding episodes (Fig. 3) . Moreover, of the 158 first infusions assessed as producing a moderate response, 73% did not require a second rFVIIIFc infusion. It is likely that these subjects rated their response as 'moderate' in the first 8 to 12 h, predicting that they would need another injection after 24 to 48 h for complete resolution and found that, in actuality, another injection was in fact not needed to resolve the bleed. Physicians' global assessment of response to rFVIIIFc was excellent or effective for 99% of the subjects' visits, and there were no subjects whose response was assessed as ineffective at any visit. Results were generally similar across treatment arms.
Population pharmacokinetic modelling of treatment of bleeding episodes
While peak factor activity level of rFVIIIFc occurs with kinetics generally similar to standard half-life products, the factor activity level following a prophylactic infusion of rFVIIIFc will be higher at all time points after the peak concentration is reached due to its reduced clearance and subsequently prolonged halflife. If treatment of an acute bleed is required, knowledge of approximate factor activity level at the time of the bleed may be useful. Table 2 shows predicted FVIII activity level at various time points after a single dose of rFVIIIFc 25, 50 or 65 IU kg À1 (e.g. when rFVIIIFc is used episodically), or following a routine prophylactic dose of rFVIIIFc. Several prophylaxis regimens were modelled, including administration of rFVIIIFc 50 IU kg À1 every 3, 4 and 5 days. A potential concern with treatment of acute bleeding episodes during prophylactic treatment is the peak factor activity level, which could theoretically contribute to adverse events if factor activity levels are above the normal range for an extended period of time. To evaluate FVIII activity when rFVIIIFc is used to treat a bleed in the context of an rFVIIIFc prophylactic regimen, a validated population pharmacokinetic model was used to predict FVIII activity in patients under several dosing scenarios that represented three common prophylactic dosing regimens in the individualized prophylaxis arm (Arm 1) during A-LONG. In the individualized prophylaxis arm, bleeding episodes rarely occurred in close proximity following a prophylactic treatment; 0.2% of prophylactic treatments were followed by a bleed within 24 h. Among the bleeding episodes occurring in the individualized prophylaxis arm, 13% of treatment infusions (last treatment infusion if >1 infusion was administered to treat the bleed) were followed by a prophylactic treatment within 24 h. Of the 301 bleeds (spontaneous and traumatic) that occurred in Arms 1 and 2, 17 bleeds (5.6%, all bleeds in Arm 1 and 0 bleeds in Arm 2) occurred within 24 h after a prophylactic dose of rFVIIIFc.
The simulations predicted that the majority of patients treating a bleed 24 h prior to their next scheduled prophylactic dose will have peak factor activity levels below the upper limit of normal (150 IU dL À1 FVIII activity [11] ) following both the dose to treat the bleed and the scheduled prophylactic dose; moreover, for the small portion of the population with peak factor activity levels >150 IU dL
À1
, the time spent >150 IU dL À1 will be brief (Fig. 4a-c) . Similarly, the simulations predicted that most patients who treat a bleed 24 h after their previous prophylactic dose will also have peak factor activity levels <150 IU dL À1 following both the dose to treat the bleed and the next scheduled prophylactic dose, and the few patients with peak factor activity levels >150 IU dL À1 will spend only a brief amount of time >150 IU dL À1 (Fig. 4d-f ).
Discussion and conclusions
These findings expand upon primary results from the A-LONG study [5] and the rFVIIIFc extension study, ASPIRE [6] , by demonstrating the efficacy of rFVIIIFc for treatment of acute bleeding episodes of different types and locations, including target joints, in subjects using rFVIIIFc for prophylactic or episodic regimens. Overall, the efficacy of rFVIIIFc for treatment of bleeding episodes was generally similar across treatment arms, with the majority of bleeds requiring one infusion for resolution, regardless of location or type. This pattern extended to traumatic bleeding episodes, with similar proportions of bleeds resolved with one infusion and similar total rFVIIIFc consumption compared with all other bleed types. No clear trend in timing of bleeding episodes with regard to prophylactic dosing was observed. The fact that the rFVIIIFc dose or dosing interval could have been adjusted based on the subject's clinical condition likely contributed to the absence of a time trend. Further separating the bleeds by dosing regimen produced a sample size that was not large enough for a robust time trend analysis. Similar to studies of conventional rFVIII products [12] [13] [14] [15] , the most common bleeding episode location during A-LONG was a joint (72%). The majority of A-LONG subjects had ≥1 target joint at baseline. rFVIIIFc was efficacious for the treatment of bleeds involving target joints, with the majority resolving These dosing scenarios were chosen to represent three common prophylactic dosing regimens in the individualized prophylaxis arm (Arm 1) during the clinical study. A treatment dose of 25 IU kg À1 was modelled, to approximate the median dose used to treat bleeding episodes during the study. An interval of 24 h between the prophylactic dose and a dose administered to treat a bleeding episode was modelled, as this would likely be the shortest potential interval between a prophylactic dose and a dose administered for treatment of bleeding. Arrows indicate the time of infusion to treat a bleeding episode or for scheduled prophylaxis, as indicated above each arrow. FVIII level) [13] . Two clinical studies of moroctocog alfa (REFACTO â ; Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA) in subjects with moderately severe to severe haemophilia A (≤2 IU dL À1 FVIII level) showed that 92.5% (subjects ≥12 years using prophylaxis; median dose, 30.6 IU kg
À1
) and 86.7% (subjects ≥6 years using prophylaxis or episodic treatment; median dose, 37.6 IU kg
) of bleeds resolved with one or two infusions [14] . Finally, in a study of turoctocog alfa (NOVOEIGHT â ; Novo Nordisk Inc., Plainsboro, NJ, USA), 89% of bleeds resolved with one or two infusions (mean consumption from start to stop of a bleed, 45.6 IU kg À1 ) in adolescents and adults with severe haemophilia A (≤1 IU dL À1 FVIII level) using prophylaxis [15] .
Pharmacokinetic data collected during A-LONG showed that maximal FVIII activity is rapidly achieved after rFVIIIFc infusion. The lower clearance of rFVIIIFc compared with rFVIII (P < 0.001 [5] ) may have contributed to the observed efficacy of rFVIIIFc for treatment of acute bleeds; for example, higher FVIII activity levels after the initial peak may have resulted in fewer bleeds requiring a second infusion for resolution.
A potential concern with treatment of acute bleeds during prophylaxis is peak factor activity level, which could theoretically contribute to adverse events such as unmasking subclinical atherosclerotic disease with subsequent vascular thrombosis if factor activity levels are elevated for an extended period of time. Given the rapid peak in FVIII activity and prolonged half-life of rFVIIIFc, we used a population pharmacokinetic model to simulate factor activity levels for rFVIIIFc treatment of bleeding in close proximity to a regular prophylactic dose, including treatment (e.g. traumatic bleed) 24 h after a prophylactic dose [this rarely occurred during the study (0.2% of prophylactic treatments)]. These simulations demonstrated that, for a small proportion of patients, predicted FVIII activity levels may briefly (i.e. for a few hours) peak >150 IU dL
. Importantly, no serious thrombotic events were reported during A-LONG, including subjects who underwent surgery with intensive dosing; a non-serious perianal venous thrombosis was reported in one subject during the postoperative period, which was likely a rectal haemorrhoid and considered mild and unrelated to rFVIIIFc by the Investigator [5] .
Determination of an appropriate dose of replacement factor for treatment of a bleeding episode has been evaluated through several generations of replacement factor products [16] [17] [18] . Here, rFVIIIFc doses used to treat bleeds were comparable to literature-reported doses for other FVIII products [19] . Importantly, appropriate treatment depends on bleed severity and location; a limitation of this study was that information on the severity of bleeds was not collected and, moreover, such information would have been difficult to standardize. In addition, there were no life-threatening bleeding episodes during A-LONG [5] , such as those involving the central nervous system or airway, and thus appropriate rFVIIIFc dosing for such an event has not yet been reported. Another limitation was the timing of subjects' assessment of response to bleeding episode treatment. The assessment was performed 8-12 h from the rFVIIIFc infusion, whereas the decision regarding a second infusion was not made until 24 h after the first infusion. Depending on the severity of the bleed, pain, swelling and reduced range of motion may remain 8-12 h after infusion, when the assessment was made, but may resolve by 24 h. Indeed, 73% of infusions rated moderate at 8-12 h did not require a second rFVIIIFc infusion. In support of the efficacy profile, overall, both subjects' assessment and physicians' global assessment of response to rFVIIIFc were favourable.
In general, the treatment dose for breakthrough bleeds for individuals on prophylaxis is outlined in the rFVIIIFc (Eloctate â ; Biogen Idec, Cambridge, MA, USA) US package insert [20] , under Dosing for Control of Bleeding Episodes. In summary, these results expand upon those previously reported for A-LONG and demonstrate that rFVIIIFc can be used to effectively treat acute bleeding episodes of any type for subjects on episodic (on-demand) or prophylaxis treatment, regardless of the severity or location of the bleeding episode, including target joints.
